Financial services

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Retrieved on: 
Monday, May 16, 2022 - 8:11am
Fungus, Novo Nordisk Foundation, Company, US Foods, Infection, Asthma, BTD, Patient, Investment, COPD, Novo Holdings A/S, Initial public offering, Bronchiectasis, FDA, Mycosis, Antifungal, Shionogi, Partnership, Board, Cancer, Growth, Novo Nordisk, Fine chemical, Pharmaceutical industry, Financial services, F2G

Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.

Key Points: 
  • Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
  • Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
  • Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Retrieved on: 
Monday, May 16, 2022 - 8:09am
Fungus, Novo Nordisk Foundation, Company, US Foods, Infection, Asthma, BTD, Patient, Investment, COPD, Novo Holdings A/S, Initial public offering, Bronchiectasis, FDA, Mycosis, Antifungal, Shionogi, Partnership, Board, Cancer, Growth, Novo Nordisk, Fine chemical, Pharmaceutical industry, Financial services, F2G

Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.

Key Points: 
  • Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
  • Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
  • Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

H.I.G. Capital Expands European Middle Market LBO Team with the Addition of Stephan Madsen

Retrieved on: 
Monday, May 16, 2022 - 8:00am
Other Consumer, Human Resources, Finance, Banking, Professional Services, Other Health, Health, Consumer, General Health, Investment, H.I.G. Capital, Whitehorse, BDC, CLO, BC Partners, Financial services, Paulo, Nordic

), a leading global alternative asset investment firm with over $49 billion of equity capital under management, announced today that Stephan Madsen has joined the firms European Middle Market LBO team in London as a Managing Director focused on the Nordic region.

Key Points: 
  • ), a leading global alternative asset investment firm with over $49 billion of equity capital under management, announced today that Stephan Madsen has joined the firms European Middle Market LBO team in London as a Managing Director focused on the Nordic region.
  • Stephan has over 12 years of private equity experience across sectors and regions, with particular focus on the Nordics.
  • Markus Noe-Nordberg, who leads H.I.G.s Middle Market fund in Europe, commented, We are very pleased to welcome Stephan Madsen to H.I.G.
  • He has a wealth of experience and will complement our team with a primary focus on the Nordic region.

Joint Press Release – Kalera and Agrico Announce Effectiveness of Registration Statement, Waiver of Minimum Cash Condition and Extraordinary General Meetings for Proposed Business Combination

Retrieved on: 
Monday, May 16, 2022 - 7:00am
Transfer, Form, U.S. Securities and Exchange Commission, Exercise, Agriculture, Internet, Register, SEC, Interim, Investment, Cayman, KAL, Proxy, Acquisition, Prospectus, GLOBE, Farm, Efficiency, Probability, Time, Communication, Reading, Aquaculture, Nasdaq, NASDAQ, Registration statement, Automation, Horticulture, RICO, LLP, Industry, Forward-looking statement, Eastern Time Zone, Technology, Sale, Person, Intelligence, Security (finance), Health insurance, Financial services, Audit, Risk management, Ugland House, Agrico Chemical Co.

Extraordinary general meeting of Kalera shareholders (the Kalera Special Meeting) and extraordinary general meeting of Agrico shareholders (the Agrico Special Meeting and, together with the Kalera Special Meeting, the Special Meetings) to approve the proposed business combination of Kalera and Agrico expected to be held on June 27, 2022.

Key Points: 
  • Extraordinary general meeting of Kalera shareholders (the Kalera Special Meeting) and extraordinary general meeting of Agrico shareholders (the Agrico Special Meeting and, together with the Kalera Special Meeting, the Special Meetings) to approve the proposed business combination of Kalera and Agrico expected to be held on June 27, 2022.
  • Kaleras shareholders of record at the close of business on the Kalera Record Date are entitled to vote their Kalera ordinary shares at the Kalera Special Meeting.
  • As announced previously, the business combination is to be effected through a newly created holding company, Kalera Public Limited Company (Kalera PLC).
  • If the business combination and other proposals are approved by Kalera and Agrico shareholders, Kalera and Agrico anticipate closing the business combination shortly after the Special Meetings, subject to the satisfaction or waiver (as applicable) of all other closing conditions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 14, 2022 - 2:00am
CEO, Risk, Company, Social media, Regulation of tobacco by the U.S. Food and Drug Administration, Volta, Food, Bear's Cave (Erpfingen), News, Patient, Defendant, Bears' Cave, Mission statement, Phenix, NASDAQ, Combination, Alfred Wegener Institute for Polar and Marine Research, Sailor, Technology, VRT, Lists of diseases, Liver function tests, Industry, Lists of schools in England, Awareness, Board, Program, PKU, Business architecture, Acquisition, Phenylketonuria, NYSE, Letter, GLOBE, Risk management, Audit, Pharmaceutical industry, Renewable energy, Financial services, P.C, Homology, Vertiv, Embark

For more information on the Vertiv class action go to: https://bespc.com/cases/VRT

Key Points: 
  • For more information on the Vertiv class action go to: https://bespc.com/cases/VRT
    Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • For more information on the Embark class action go to: https://bespc.com/cases/EMBK
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 14, 2022 - 2:00am
CEO, Risk, Company, Social media, Regulation of tobacco by the U.S. Food and Drug Administration, Volta, Food, Bear's Cave (Erpfingen), News, Patient, Defendant, Bears' Cave, Mission statement, Phenix, NASDAQ, Combination, Alfred Wegener Institute for Polar and Marine Research, Sailor, Technology, VRT, Lists of diseases, Liver function tests, Industry, Lists of schools in England, Awareness, Board, Program, PKU, Business architecture, Acquisition, Phenylketonuria, NYSE, Letter, GLOBE, Risk management, Audit, Pharmaceutical industry, Renewable energy, Financial services, P.C, Homology, Vertiv, Embark

For more information on the Vertiv class action go to: https://bespc.com/cases/VRT

Key Points: 
  • For more information on the Vertiv class action go to: https://bespc.com/cases/VRT
    Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • For more information on the Embark class action go to: https://bespc.com/cases/EMBK
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

$83 Million Grocery-Anchored Shopping Center Sale in North Carolina Closed by Institutional Property Advisors

Retrieved on: 
Friday, May 13, 2022 - 11:06pm
Retail, Restaurant, Bar, Department Stores, Supermarket, Commercial Building & Real Estate, Specialty, Construction & Property, Sprouts, IPA, DSW, Petco, Marcus & Millichap, Buy Buy Baby, MMI, Research, World market, NYSE, Sale, Field & Stream, Hobby Lobby, Acquisition, Financial services

Institutional Property Advisors (IPA), a division of Marcus & Millichap (NYSE:MMI), announced the sale of Freedom Town Center, a 350,800-square-foot grocery-anchored shopping center in Fayetteville, North Carolina.

Key Points: 
  • Institutional Property Advisors (IPA), a division of Marcus & Millichap (NYSE:MMI), announced the sale of Freedom Town Center, a 350,800-square-foot grocery-anchored shopping center in Fayetteville, North Carolina.
  • Over 99% occupied at the time of the sale by a roster of top national tenants, Freedom Town Center serves more than 4 million customers annually, said Steven Siegel, IPA senior managing director.
  • Ben Yelm, vice president and regional manager, is Marcus & Millichaps broker of record in North Carolina.
  • Institutional Property Advisors (IPA) is a division of Marcus & Millichap (NYSE:MMI), a leading commercial real estate services firm in North America.

LATHAM & WATKINS PUBLISHES LATEST EDITION OF PRIVATE CAPITAL INSIGHTS

Retrieved on: 
Friday, May 13, 2022 - 10:05pm
Latham & Watkins, Real, Foreign Legal Consultant, AUM, Lawyer, Investment, Law, COVID-19, Watkins, United Kingdom, Appetite, Partnership, Kingdom, Capital, CLO, Bed, Growth, Han Kun Law Offices, ESG, Bank, Financial services

LONDON, May 13, 2022 /PRNewswire/ -- Latham & Watkins LLP is pleased to announce the launch of the latest edition of Private Capital Insights, a comprehensive report examining key global trends and developments impacting private capital investors, lenders, sponsors and other market participants across a range of asset classes and private capital strategies.

Key Points: 
  • LONDON, May 13, 2022 /PRNewswire/ -- Latham & Watkins LLP is pleased to announce the launch of the latest edition of Private Capital Insights , a comprehensive report examining key global trends and developments impacting private capital investors, lenders, sponsors and other market participants across a range of asset classes and private capital strategies.
  • With private capital assets under management (AUM) exceeding US$11.9trn in 2021* - an increase of 50% over the last two years - the latest edition of Private Capital Insights discusses the continued global growth and impact of private funds, and explores the drivers of future demand across direct lending, infrastructure, real estate, private equity, distressed debt, structured credit, and growth capital.
  • "The strong growth and influence of private funds has continued apace," said Paul Sheridan, Global Co-Chair of Private Capital at Latham & Watkins and partner in the Washington, D.C. office.
  • Latham & Watkins works in cooperation with the Law Office of Salman M. Al-Sudairi in the Kingdom of Saudi Arabia.

Cornerstone Funds Announce Continuing Monthly Distributions

Retrieved on: 
Friday, May 13, 2022 - 9:30pm
Income, Risk, U.S. Securities and Exchange Commission, Disclosure, Adviser, Investment, Policy, Judgement, Excess, Industry, NYSE American, Board, Board of directors, Sale, Calendar, Regulation, LLC, Life insurance, Financial services, Bank, Fund

These distributions are not tied to each Funds investment income or capital gains and do not represent yield or investment return on each Funds portfolio.

Key Points: 
  • These distributions are not tied to each Funds investment income or capital gains and do not represent yield or investment return on each Funds portfolio.
  • Stockholders may consider reinvesting their regular distributions through their Funds reinvestment plan which may at times provide additional benefit to stockholders who participate in their Funds plan.
  • In determining to adopt this policy, the Board of each Fund sought to make regular monthly distributions throughout the year.
  • In any given year, there can be no guarantee each Funds investment returns will exceed the amount of the net distributions.

LATHAM & WATKINS PUBLISHES LATEST EDITION OF PRIVATE CAPITAL INSIGHTS

Retrieved on: 
Friday, May 13, 2022 - 9:41pm
Latham & Watkins, Real, Foreign Legal Consultant, AUM, Lawyer, Multimedia, Investment, Law, COVID-19, Watkins, United Kingdom, Appetite, Partnership, Kingdom, Capital, CLO, Bed, Growth, Han Kun Law Offices, ESG, Bank, Financial services

LONDON, May 13, 2022 /PRNewswire/ -- Latham & Watkins LLP is pleased to announce the launch of the latest edition of Private Capital Insights, a comprehensive report examining key global trends and developments impacting private capital investors, lenders, sponsors and other market participants across a range of asset classes and private capital strategies.

Key Points: 
  • LONDON, May 13, 2022 /PRNewswire/ -- Latham & Watkins LLP is pleased to announce the launch of the latest edition of Private Capital Insights , a comprehensive report examining key global trends and developments impacting private capital investors, lenders, sponsors and other market participants across a range of asset classes and private capital strategies.
  • With private capital assets under management (AUM) exceeding US$11.9trn in 2021* - an increase of 50% over the last two years - the latest edition of Private Capital Insights discusses the continued global growth and impact of private funds, and explores the drivers of future demand across direct lending, infrastructure, real estate, private equity, distressed debt, structured credit, and growth capital.
  • "The strong growth and influence of private funds has continued apace," said Paul Sheridan, Global Co-Chair of Private Capital at Latham & Watkins and partner in the Washington, D.C. office.
  • Latham & Watkins works in cooperation with the Law Office of Salman M. Al-Sudairi in the Kingdom of Saudi Arabia.